| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | -14.31% | Goldman Sachs | $4 → $1.25 | Maintains | Sell |
| 06/26/2023 | 722.65% | Oppenheimer | → $12 | Assumes | → Outperform |
| 04/28/2023 | 585.54% | Chardan Capital | $12 → $10 | Maintains | Buy |
| 04/21/2023 | 379.88% | JP Morgan | → $7 | Initiates Coverage On | → Neutral |
| 03/21/2023 | 928.31% | Canaccord Genuity | $11 → $15 | Maintains | Buy |
| 03/08/2023 | 654.1% | Canaccord Genuity | $17 → $11 | Maintains | Buy |
| 03/08/2023 | 722.65% | Chardan Capital | → $12 | Reiterates | → Buy |
| 03/08/2023 | 1613.85% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/08/2023 | 1613.85% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 09/07/2022 | 516.99% | Piper Sandler | $7 → $9 | Maintains | Overweight |
| 05/23/2022 | 379.88% | Piper Sandler | $32 → $7 | Maintains | Overweight |
| 07/23/2021 | 1888.07% | Canaccord Genuity | $42 → $29 | Maintains | Buy |
| 07/23/2021 | 996.87% | Chardan Capital | $30 → $16 | Maintains | Buy |
| 07/23/2021 | 1133.98% | Oppenheimer | $36 → $18 | Maintains | Outperform |
| 07/23/2021 | 1613.85% | HC Wainwright & Co. | $46 → $25 | Maintains | Buy |
| 07/23/2021 | 379.88% | Goldman Sachs | $24 → $7 | Downgrades | Neutral → Sell |
| 05/05/2021 | 3053.49% | HC Wainwright & Co. | $41 → $46 | Maintains | Buy |
| 03/05/2021 | 1956.63% | Chardan Capital | $27.5 → $30 | Upgrades | Neutral → Buy |
| 12/23/2020 | — | JMP Securities | Initiates Coverage On | → Market Perform | |
| 09/21/2020 | 2779.28% | Canaccord Genuity | $38 → $42 | Maintains | Buy |
| 09/18/2020 | 1785.24% | Chardan Capital | → $27.5 | Downgrades | Buy → Neutral |
| 08/18/2020 | 2642.17% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 08/11/2020 | 2710.72% | HC Wainwright & Co. | $8 → $41 | Maintains | Buy |
| 08/11/2020 | 1888.07% | Jefferies | $4 → $29 | Upgrades | Hold → Buy |
| 08/11/2020 | 2128.01% | Chardan Capital | $12.5 → $32.5 | Maintains | Buy |
| 03/31/2020 | 379.88% | Oppenheimer | $8 → $7 | Maintains | Outperform |
| 04/30/2019 | 379.88% | Jefferies | → $7 | Initiates Coverage On | → Hold |
What is the target price for Seres Therapeutics (MCRB)?
The latest price target for Seres Therapeutics (NASDAQ: MCRB) was reported by Goldman Sachs on November 3, 2023. The analyst firm set a price target for $1.25 expecting MCRB to fall to within 12 months (a possible -14.31% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Seres Therapeutics (MCRB)?
The latest analyst rating for Seres Therapeutics (NASDAQ: MCRB) was provided by Goldman Sachs, and Seres Therapeutics maintained their sell rating.
When is the next analyst rating going to be posted or updated for Seres Therapeutics (MCRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seres Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seres Therapeutics was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Seres Therapeutics (MCRB) correct?
While ratings are subjective and will change, the latest Seres Therapeutics (MCRB) rating was a maintained with a price target of $4.00 to $1.25. The current price Seres Therapeutics (MCRB) is trading at is $1.46, which is out of the analyst's predicted range.